Tavarua

Braza increases its capital by R$ 50 million and prepares for international expansion

Retrieved on: 
Wednesday, May 31, 2023
Tavarua, Central bank, Institution, Risk management, Lead, Organizational culture, BRL, Central Bank of Brazil, Investment, Branch, Bank, Financial services

SÃO PAULO, May 31, 2023 /PRNewswire/ -- Braza – a group of companies operating since 2007 with financial solutions for international payments and transfers, including Braza Bank (a foreign exchange Bank in Brazil), Braza UK (an E-Money institution based in England), Braza PT (Branch in Portugal), Braza Tech (technology) and CloudBreak (multicurrency account), advances in the organization of its capital structure to offer more and more services to citizens and global companies.

Key Points: 
  • This capital increase, most of which will go to the financial institution Braza Bank, has been already approved by Brazilian central bank.
  • Only in the last four years, it carried out around 10 million transactions, with a volume that exceeds R$ 300 billion.
  • In addition, more than 6 million people and 7 thousand companies have transacted with the Institution.
  • Since 2022, the group has quadrupled the number of employees and made investments in technology, cyber security, data infrastructure, governance, risk management, brand change, and expansion of financial products.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Therapy, Biotechnology, Research, CD73, Tavarua, CDTX, DFC, Patient, SAN, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Conference, Food, Pharmaceutical industry, Medical device, Cryptocurrency, Security (finance), Melinta Therapeutics

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline.

Key Points: 
  • SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline.
  • Revenue totaled $26.0 million for the three months ended March 31, 2023, compared with $7.1 million for the same period in 2022.
  • The increase was primarily attributable to the revenue recognized in connection with the Melinta regulatory milestone achieved in March 2023.
  • As of March 31, 2023, Cidara had 90,024,562 shares of common stock outstanding and 2,104,472 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 21,044,720 shares of common stock.

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

Retrieved on: 
Wednesday, May 3, 2023
Drug, Janssen Pharmaceuticals, Therapy, Influenza, Neuraminidase, Biotechnology, H3N2, Janssen, PT, CD73, Tavarua, CDTX, DFC, Patient, SAN, Johnson & Johnson, IND, International Society, Safety, Vaccine, Pharmaceutical industry

“These encouraging CD388 preclinical data provide further support for the potential of our Cloudbreak® DFC programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • “These encouraging CD388 preclinical data provide further support for the potential of our Cloudbreak® DFC programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • “CD388 has shown potential activity against seasonal and pandemic influenza strains, as well as activity against influenza strains resistant to neuraminidase inhibitors, the current standard of care.
  • The in vitro potency of CD388 translated into a high level of protection in mouse survival and quantitative lung burden treatment models.
  • Cidara is additionally advancing its first oncology DFC candidate, CD421, a first-in-class inhibitor of CD73, with an IND anticipated in 2024.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Restore, Neoplasm, Food and Drug Administration, CDTX, Adenosine, Congress, Janssen Pharmaceuticals, Patent, Patient, Therapy, Food, Research, Panel, FDA, IND, Conference, Safety, 1836 U.S. Patent Office fire, February 13–17, 2021 North American winter storm, Biotechnology, ESMO, H3N2, Tavarua, Standard of care, Caspofungin, SAN, Escape Room, Johnson & Johnson, DFC, Wuxi, CMC, NDA, CD73, Viral disease, Cantor Fitzgerald, Respect, Treatment, Pharmaceutical industry, Security (finance), Vaccine, Cryptocurrency, Janssen, Melinta Therapeutics, Lancet, Fungemia

This approval enables Cidara to receive a $20.0 million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • This approval enables Cidara to receive a $20.0 million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • In addition, we announced the nomination of our first oncology DFC candidate, CBO-212, and presented preclinical data at the ESMO-TAT conference.
  • We are currently conducting investigational new drug (IND)-enabling activities for CD421, which is an enhanced version of CBO-212.
  • The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $19.5 million.

Element to Present Data and Innovation Roadmap at AGBT

Retrieved on: 
Monday, February 6, 2023
Cloud, Sequence, ECP, House, Q&A, Workflow, Biochemistry, SVP, Manhattan Center, Hi-C (genomic analysis technique), Q42, Elevate, Mass meeting, Avidity, Chemistry, SAN, Innovation, Grande Ballroom, Genomics, John J. Carty Award for the Advancement of Science, Overalls, Great hall, Genome, Doctor of Philosophy, Fine chemical, Management, Element, Tavarua, Informatics, Software, Q40

SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — will present details about its new Avidity Cloudbreak™ technology and the company's innovation roadmap at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 6-9, 2023, in Hollywood, FL.

Key Points: 
  • Element provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.
  • Element will present customer data on exome sequencing reporting the majority of bases on AVITI are >Q42, the first commercial platform consistently delivering data quality in excess of Q40.
  • Join Element for a series of talks at AGBT, including:
    Jon Armstrong, VP of Research & Development, Jumpcode Genomics, will present "Boost your single cell studies with CRISPRclean and AVITI: Sequence less and see more usable data."
  • Matthew Kellinger, PhD, Element VP of Biochemistry and Co-Founder, will present data on Element's technology and future outlook in an AGBT Bronze Workshop talk, "Cloudbreak and Beyond: A Roadmap for Innovation" at 2:40 p.m. in the Grand Ballroom.

Element Drives Industry Innovation with New Avidity Cloudbreak™ Technology and a 2 x 300 Kit

Retrieved on: 
Wednesday, December 7, 2022
Chemistry, Biochemistry, Elevate, Workflow, Doctor of Philosophy, Biomarker, Science, Element, Research, Liquid biopsy, Genomics, Lightning, SAN, Computer data storage, Cassette tape, Fine chemical, Tavarua

SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Element Biosciences, Inc.—developer of an innovative DNA sequencing platform that is disrupting the genomics industry—today announced Avidity Cloudbreak technology, improvements to chemistry kits for the current Element AVITI™ System that reduce run times and enable even more applications.

Key Points: 
  • Less than one year after launching the AVITI System, Element continues to rapidly advance its technology and expand product offerings.
  • Avidity Cloudbreak will further enable Element to release a 2x 300 sequencing kit, earmarked for 2023.
  • "Development of the Cloudbreak chemistry demonstrates Element's constant commitment to push the envelope on our technology.
  • Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing technology for research and diagnostic markets.

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Degenerative disease, 1836 U.S. Patent Office fire, DFC (cipher), SAN, Tavarua, Peptide, Immune system, Pharmacokinetics, Nose, DFC, Risk, Therapy, Biotechnology, Patient, Viral envelope, Janssen, CDTX, Drug Quality and Security Act, Viral disease, Patent, Security (finance), Death, Vaccine, Severe acute respiratory syndrome coronavirus 2, Infection, Treatment, Safety, Pharmaceutical industry

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.
  • The patent is the first issued for CD388, and includes claims directed to the composition of matter of CD388.
  • The patent is projected to expire in 2039 plus any available patent term extension.
  • We are pleased to receive the first U.S. patent for our lead flu DFC, CD388, as we establish robust IP protection for this new class of drug, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
File, Private Securities Litigation Reform Act, Research, Therapy, LLC, SAN, Food, EMA, Biotechnology, DFC (cipher), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fungemia, GLOBE, European Medicines Agency, Restore, FDA, Safety, Priority review, Pharmacokinetics, Adult, Conference, Securities Exchange Act of 1934, Tavarua, COVID-19, QIDP, Standard of care, Marketing, Income, Securities Act of 1933, NDA, U.S. Securities and Exchange Commission, PDUFA, New Drug Application, ID, Forward-looking statement, MAA, NASDAQ, Drug Quality and Security Act, Partnership, Security (finance), Candidiasis, Volunteering, Mycosis, Achievement, Patient, CDTX, Pharmaceutical industry, Vaccine, Medical device, Aquaculture, Janssen, Mundipharma, Melinta Therapeutics

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2022 and provided an update on its corporate activities and product pipeline.

Key Points: 
  • SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2022 and provided an update on its corporate activities and product pipeline.
  • Announced license agreement with Melinta Therapeutics, LLC: In July 2022, Cidara announced it entered into a license agreement with Melinta Therapeutics, LLC (Melinta) under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the U.S.
  • Cidara retains the rights to rezafungin in Japan, while Mundipharma retains the commercial rights to rezafungin outside the U.S. and Japan.
  • Presented new data for rezafungin at IDWeek 2022: In October 2022, Cidara presented new clinical and preclinical data for rezafungin in six poster presentations at IDWeek 2022.

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

Retrieved on: 
Tuesday, October 4, 2022
Melinta Therapeutics, Securities Act of 1933, Association, Securities Exchange Act of 1934, NASDAQ, Adult, Time, Respect, QIDP, Private Securities Litigation Reform Act, Drug Quality and Security Act, U.S. Securities and Exchange Commission, Fungemia, Restore, FDA, COVID-19, CDTX, MAA, Therapy, Safety, Biotechnology, Janssen, SAN, European Medicines Agency, Security (finance), Patient, Forward-looking statement, New Shrimadhopur DFC Station, EMA, Tavarua, Marketing, GLOBE, Mycosis, Pharmaceutical industry, Mundipharma, EU

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) --  Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced receipt of an $11 million milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019. The payment was made in association with the European Medicines Agency (EMA) acceptance of the marketing authorization application (MAA) for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients.

Key Points: 
  • SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced receipt of an $11 million milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019.
  • With the $11 million milestone payment from Mundipharma, Cidara remains eligible to receive additional non-dilutive capital of up to approximately $108 million in development and regulatory milestones from our existing partnerships based on successful completion of activities planned for the next two years, said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara.
  • Cidara retains the rights to rezafungin in Japan and has licensed the commercial rights to Melinta Therapeutics in the U.S. and Mundipharma Medical in all other geographies.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

Retrieved on: 
Tuesday, September 13, 2022
CDTX, Securities Exchange Act of 1934, Therapy, Volunteering, Janssen Pharmaceuticals, Safety, Human, COVID-19, Risk, Drug Quality and Security Act, DFC, Severe acute respiratory syndrome coronavirus 2, Private Securities Litigation Reform Act, Degenerative disease, Securities Act of 1933, Viral envelope, Nose, Forward-looking statement, U.S. Securities and Exchange Commission, Infection, Patient, Johnson & Johnson, Tavarua, Standard of care, Vaccine, DFC (cipher), Immunodeficiency, Nasdaq, SAN, Security (finance), Biotechnology, Pharmacokinetics, Janssen, GLOBE, Immune system, Cancer, Peptide, Death, Pharmaceutical industry

SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak® drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza.

Key Points: 
  • CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza.
  • Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge.
  • Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems.
  • For influenza, the long-acting CD388 DFC is designed to directly inhibit viral proliferation by targeting a conserved region on the viral envelope, potentially conferring universal prevention of Types A and B influenza with a single seasonal dose.